← Leaderboards
Raushan Kurmasheva
University Of Texas Hlth Science Center
$2,024,146
Attributed
$2,862,121
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600.7K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,862,121 · 1
By mechanism
U01$2,862,121 · 1
Top collaborators
- Peter J Houghton3 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Peter J Houghton$32,798,876
- Angelina V Vaseva$1,395,448
Others in their field
Other Emerging Leaders on “Databases”
- Leonard Freedman · Leidos Biomedical Research, Inc.$186,439,178
- Klaus Romero · Critical Path Institute$90,404,592
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$68,745,882
- Leonard Freedmand · Leidos Biomedical Research, Inc.$50,302,300
- Lynn Briscoe · Leidos Biomedical Research, Inc.$50,165,970
Research focus
DatabasesCyclophosphamideClinical TrialsCombined Modality TherapyAdoptedAntitumor EffectAdolescentClinical DevelopmentClinical ResearchClinical Trials DesignAntibody-Drug ConjugatesBrain NeoplasmsCancer CellCancer TypeCd276 GeneCell LineCharacteristicsChemoradiationChemotherapyChildChildhoodChildhood Cancer TreatmentChildhood Solid NeoplasmDesign
Grant awards (5)
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$593,085
U01 · FY2025 · CA · contact PI
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$593,085
U01 · FY2024 · CA · contact PI
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$487,604
U01 · FY2023 · CA · contact PI
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$587,662
U01 · FY2022 · CA
A Testing Program to Identify Novel Agents for Treatment of Pediatric and AYA High-Risk Sarcoma, Kidney and Liver Cancer$600,685
U01 · FY2021 · CA